-
Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma
•
Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for sugemalimab, a programmed death-ligand 1 (PD-L1) inhibitor, for the first-line treatment of inoperable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma (G/GEJ) expressing…
-
Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults
•
The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’ (NASDAQ: MDGL) Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) in adults with moderate-to-advanced liver fibrosis. This marks the first approval in the US for a therapy indicated for liver scarring due to…
-
Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia
•
Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in China and Indonesia, according to its 2023 annual report. This strategic shift follows a record year for the firm, which saw underlying profits reach HKD 36.2 billion (USD 4.63 billion). In March, Swire reached an…
-
CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars
•
The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held by Denmark-based Novo Nordisk (NYSE: NVO) related to Victoza (liraglutide) and its stable preparation of proinsulin peptide. This patent was challenged by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a subsidiary of China’s Huadong Medicine Co.,…
-
CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure
•
The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two patents associated with AbbVie (NYSE: ABBV)’s JAK inhibitor, upadacitinib, listed in China’s version of the ‘Orange Book’. This ruling, highlighted by Lusheng Law Firm’s Terry Lu, could set a critical precedent for innovative pharmaceutical companies,…
-
BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries
•
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that the first patients have received doses of Brukinsa (zanubrutinib) through a charitable access initiative designed to provide the drug to patients in low- and middle-income countries (LMICs). This initiative is made possible by a partnership…
-
Innovent Biologics Denies Lab Closure, Confirms Relocation to California
•
Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland lab, stating instead that the facility is being relocated to California. The clarification follows a report by Yicai, which indicated potential downsizing at the Maryland site. However, Innovent has not disclosed a timeline for the…
-
Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline
•
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a subsidiary of US biopharmaceutical company IFM Therapeutics, for an upfront payment of $90 million, with potential milestone payments totaling up to $745 million. This acquisition builds on a 2019 agreement in which Novartis financed IFM…
